NervGen Pharma Grants Stock Options
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical stage biotech company focused on treating nervous system damage, has granted stock options to employees and consultants. The company issued 30,000 options to employees, exercisable at $2.98 per share for 10 years, vesting equally every six months over two years. Additionally, 15,000 options were granted to existing consultants providing investor relations services, exercisable at the same price for five years, vesting equally every three months over one year. These options comply with TSX Venture Exchange policies and the company's stock option plan.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), un'azienda biotecnologica in fase clinica focalizzata sul trattamento dei danni al sistema nervoso, ha concesso opzioni su azioni a dipendenti e consulenti. L'azienda ha emesso 30.000 opzioni ai dipendenti, esercitabili a 2,98 $ per azione per 10 anni, con maturazione uniforme ogni sei mesi per un periodo di due anni. Inoltre, 15.000 opzioni sono state concesse ai consulenti esistenti che offrono servizi di relazioni con gli investitori, esercitabili allo stesso prezzo per cinque anni, con maturazione uniforme ogni tre mesi per un anno. Queste opzioni sono conformi alle politiche della Borsa TSX Venture e al piano di opzioni su azioni dell'azienda.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), una empresa biotecnológica en etapa clínica centrada en el tratamiento de daños en el sistema nervioso, ha otorgado opciones sobre acciones a empleados y consultores. La empresa emitió 30,000 opciones a empleados, ejercitables a $2.98 por acción durante 10 años, con derecho a ejercitarse equitativamente cada seis meses durante dos años. Además, se otorgaron 15,000 opciones a consultores existentes que proporcionan servicios de relaciones con inversores, ejercitables al mismo precio durante cinco años, con derecho a ejercitarse equitativamente cada tres meses durante un año. Estas opciones cumplen con las políticas de la Bolsa de Valores TSX Venture y el plan de opciones sobre acciones de la empresa.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF)는 신경계 손상 치료에 중점을 두고 있는 임상 단계의 생명공학 회사로, 직원 및 컨설턴트에게 주식 옵션을 부여했습니다. 회사는 직원에게 30,000개의 옵션을 발행했습니다, 10년 동안 주당 2.98달러에 행사 가능하며, 2년 동안 6개월마다 균등하게 행사됩니다. 추가로, 15,000개의 옵션이 투자자 관계 서비스를 제공하는 기존 컨설턴트에게 부여되었습니다, 5년 동안 같은 가격에 행사 가능하며, 1년 동안 3개월마다 균등하게 행사됩니다. 이러한 옵션은 TSX 벤처 거래소의 정책 및 회사의 주식 옵션 계획을 준수합니다.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), une entreprise biopharmaceutique en phase clinique axée sur le traitement des lésions du système nerveux, a accordé des options d'achat d'actions à ses employés et consultants. L'entreprise a émis 30 000 options aux employés, exerçables à 2,98 $ par action pendant 10 ans, acquérant des droits de manière égale tous les six mois sur deux ans. De plus, 15 000 options ont été accordées à des consultants existants fournissant des services de relations avec les investisseurs, exerçables au même prix pendant cinq ans, acquérant des droits de manière égale tous les trois mois sur un an. Ces options sont conformes aux politiques de la Bourse TSX Venture et au plan d'options d'achat d'actions de l'entreprise.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von Nervenschäden konzentriert, hat Aktienoptionen an Mitarbeiter und Berater vergeben. Das Unternehmen hat 30.000 Optionen an Mitarbeiter vergeben, die für 10 Jahre zu einem Preis von 2,98 $ pro Aktie ausgeübt werden können, wobei die Optionen in zwei Jahren alle sechs Monate gleichmäßig fällig werden. Darüber hinaus wurden 15.000 Optionen an bestehende Berater vergeben, die Dienstleistungen im Bereich Anlegerbeziehungen anbieten und für fünf Jahre zu demselben Preis ausgeübt werden können, wobei sie in einem Jahr alle drei Monate gleichmäßig fällig werden. Diese Optionen entsprechen den Richtlinien der TSX Venture Exchange und dem Aktienoptionsplan des Unternehmens.
- Incentivizing employees and consultants with stock options may improve retention and align interests with shareholders
- Gradual vesting schedule over 1-2 years encourages long-term commitment
- Potential dilution of existing shareholders' ownership
- Increased share-based compensation expense may impact financial results
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 30,000 incentive stock options to employees of the company and 15,000 incentive stock options to existing consultants providing investor relations services exercisable at a price of
About NervGen
NervGen is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen's lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company's initial target indication, spinal cord injury. The company has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. For more information, visit www.nervgen.com and follow NervGen on X, LinkedIn, and Facebook for the latest news on the company.
Contacts
Huitt Tracey, Corporate Communications
htracey@nervgen.com
604.537.2094
Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218738
FAQ
How many stock options did NervGen Pharma (NGENF) grant to employees?
What is the exercise price of the stock options granted by NervGen Pharma (NGENF) on August 2, 2024?
What is the vesting schedule for the employee stock options granted by NervGen Pharma (NGENF)?
How many stock options did NervGen Pharma (NGENF) grant to consultants?
